Moomoo AI 已提取核心信息
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on January 16, 2024. The shares, valued at an aggregate market value of $1,250,056, were acquired on the same date through the exercise of stock options directly from the issuer. The transaction will be settled in cash. This planned sale follows a period where no securities transactions were reported by Kulkarni in the past three months, as per the latest filings.
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on January 16, 2024. The shares, valued at an aggregate market value of $1,250,056, were acquired on the same date through the exercise of stock options directly from the issuer. The transaction will be settled in cash. This planned sale follows a period where no securities transactions were reported by Kulkarni in the past three months, as per the latest filings.
同时担任高管兼董事的CRISPR Therapeutics高管萨玛斯·库尔卡尼定于2024年1月16日出售2万股普通股。这些股票的总市值为1,250,056美元，是同日通过直接向发行人行使股票期权收购的。该交易将以现金结算。根据最新文件，此次计划出售是在库尔卡尼在过去三个月中没有报告任何证券交易之后进行的。
同时担任高管兼董事的CRISPR Therapeutics高管萨玛斯·库尔卡尼定于2024年1月16日出售2万股普通股。这些股票的总市值为1,250,056美元，是同日通过直接向发行人行使股票期权收购的。该交易将以现金结算。根据最新文件，此次计划出售是在库尔卡尼在过去三个月中没有报告任何证券交易之后进行的。
有用
没用